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Background: Interferon Regulatory Factor 5 is a transcription factor that regulates the expression of genes involved
in the response to viral infection and in the stimulation of the immune system. Moreover, multiple studies have
demonstrated that it negatively regulates cell growth and oncogenesis, favoring cell differentiation and apoptosis.
Thyroid carcinoma represents 98% of all thyroid malignancies and has shown a steady increase in incidence in both
the USA and western European countries.
Findings: We investigated the expression, localization and function of IRF5 in thyroid cancer cells and found that it
is highly expressed in both primary and immortalized thyroid carcinomas but not in normal thyrocytes. IRF5 levels
were variably modulated by Interferon alpha but IRF5 only localized in the cytoplasmic compartment, thus failing to
induce p21 expression as previously reported in different cell models. Furthermore, ectopic IRF5 increased both the
proliferation rate and the clonogenic potential of malignant thyroid cells, protecting them from the cytotoxic
effects of DNA-damaging agents. These results were directly attributable to IRF5, as demonstrated by the reduction
in colony-forming ability of thyroid cancer cells after IRF5 silencing. An IRF5-dependent induction of endogenous
B-Raf observed in all thyroid cancer cells might contribute to these unexpected effects.
Conclusions: These findings suggest that, in thyroid malignancies, IRF5 displays tumor-promoting rather than
tumor-suppressor activities.
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Interferon Regulatory Factor 5 plays essential roles in the
regulation of genes induced by viral infection, cell growth,
oncogenesis and apoptosis [1-8]. IRF5 was identified as a
regulator of type I Interferon [9] and further studies
revealed that IRF5 displays some tumor-suppressor proper-
ties as it can induce p21, Bak, Bax, and Caspase 8 [10-12].
Thyroid carcinoma represents a unique model to study
human carcinogenesis because it comprises tumors with
different clinical and histological features [13]. Indeed,
papillary and follicular thyroid cancers are slow-growing,
well differentiated tumors, whereas anaplastic thyroid
cancers are undifferentiated neoplasias that behave
much more aggressively, usually leading to the death of
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distribution, and reproduction in any mediumWe have analyzed the expression and function of IRF5
in thyroid carcinoma cells and report here multiple evi-
dence suggesting that IRF5 may contribute to thyroid
cancer proliferation and survival.
Findings
IRF5 is expressed in human thyroid cancer cells and is
variably modulated by IFNα
To investigate IRF5 expression in both normal and neo-
plastic thyrocytes, we collected specimens derived from
seven normal thyroids and three thyroid carcinomas as
previously described [16]. We also examined four immor-
talized thyroid cancer cell lines (SW1736, WRO, 8305C
and C643) all cultured as reported elsewhere [16]. An
anti-IRF5 immunoblot found low or undetectable expres-
sion in normal thyrocytes. On the contrary, primary and
immortalized thyroid cancer cells expressed high levels of
IRF5, suggesting a possible role for this protein in thyroid
carcinogenesis (Figure 1A). Interferon alpha (IFNα) is atral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,















































































































Figure 1 IRF5 is expressed in neoplastic thyrocytes. A. Specimens obtained from seven normal (N) thyrocytes, three patients with thyroid
cancer (T) and the indicated immortalized cell lines were analyzed for IRF5 expression. Lysates from each sample were subjected to immunoblot
using an anti-IRF5 antibody (Abcam). B. Two normal (N) and two neoplastic thyroid specimens (T) were treated with IFNα and subsequently
analyzed by SDS-PAGE with the same antibody employed in A. C. Lysates from the specified cell lines were used to perform anti-IRF5
immunoblots (left panels) before and after exposure to IFNα (Sigma) for the indicated times. Densitometric analysis of the corresponding
immunoblots is depicted in histograms (right panel) representing IRF5 expression after 24 (white columns) or 48 hour (black columns) of IFNα
treatment. IRF5 levels in untreated cells are arbitrarily set at 1 (dashed line). Columns represent average ± standard deviation of three independent
experiments.
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its efficacy on IRF5 induction in thyroid cancer cells is still
unknown. We therefore exposed normal and neoplastic
thyrocytes or the above-indicated thyroid cell lines to
1000U/mL IFNα and performed anti-IRF5 immunoblots.
Unexpectedly, IFNα failed to induce IRF5 in primary thyr-
ocytes (Figure 1B) causing instead modest variations in
8305C cells and stronger reductions - albeit with different
kinetics - in WRO and C643 (Figure 1C). SW1736 were
the only thyroid cancer line that displayed a robust up-
regulation in IRF5 expression after IFNα.IRF5 lacks tumor-suppressor activity in thyroid
cancer cells
At steady state, IRF5 localizes to the cell cytoplasm. How-
ever, two Nuclear Localization Signals and a Nuclear
Export Signal regulate IRF5 subcellular localization [18],
promoting its nuclear import after viral infection [19]. To
assess IRF5 intracellular distribution, we isolated nuclear
and cytoplasmic fractions from four thyroid cancer cells
using the Qproteom Nuclear Protein Kit (Qiagen). Immu-
noblots showed that IRF5 localized in the cytoplasmic
compartment of each cell line, regardless of IFNα
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Figure 2 (See legend on next page.)
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Figure 2 IRF5 localizes in the cytoplasm and lacks tumor-suppressor activity in thyroid cancer cells. A. Cytoplasmic (C), soluble (NX1) and
insoluble (NX2) nuclear fractions were isolated from the indicated cell lines before and after a 24 hour treatment with IFNα. The different lysates
were then blotted for IRF5. Tubulin (Tub) and histone 2B (H2B) (both from Santa Cruz) confirmed the purity of cytoplasmic and nuclear extracts.
B. The same cells were subjected to IF for IRF-5 using the indicated secondary antibody. Hoechst and phalloidin (Alexa Fluor 488) were employed
to identify the nuclear and cytoplasmic compartments, respectively. C. Thyroid cancer cell lines were also co-transfected with a reporter construct
for p21 and p53-GFP or IRF5-GFP. After 48 hours, lysates were assayed for their relative luciferase activity expressed as fold activation over control
cells (p21Luc + EV, arbitrarily set at 1). Results shown represent the average of three independent experiments. D. Alternatively, the same
co-transfected cells were blotted using either anti-p21 (Santa Cruz) or anti-GFP antibodies (Covance), the latter to visualize either p53 or IRF5.
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confirmed by immunofluorescence (IF) experiments
carried out before and after IFNα treatment (Figure 2B
and Additional file 1).
We next wanted to establish the transcriptional activ-
ity of IRF5 on genes involved in cell-cycle progression.
SW1736, WRO, 8305C, and C643 were co-transfected
(using Fugene-6 from Roche) with p21-Luc (p21 pro-
moter driving the luciferase reporter gene) and GFP-
IRF5 variant 3 (kindly provided by P.M. Pitha, Baltimore,














































































Figure 3 IRF5 promotes thyroid cancer cells proliferation. A. The spec
analyzed for infection efficiency with an anti-GFP immunoblot. B. 5 × 103 th
for 24 (white columns), 48 (light grey columns), 72 (dark grey columns) and
lines indicate baseline proliferation rates for each cell line assessed 4 hours
cells were implanted in 24-well plates and, after 72 hours, employed to cal
(http://www.doubling-time.com/compute.php). p-values with 95% confiden
Software (GraphPad Software, *p< 0.05, **p< 0.01, *** p< 0.001).(EV, negative control). Luciferase activity was then
analyzed with the Dual-LuciferaseW Reporter Assay kit
(Promega). Unlike p53, IRF5 failed to induce p21-Luc
activity (Figure 2C) as confirmed by anti-p21 immu-
noblots (Figure 2D).
IRF5 induces the proliferation of thyroid cancer cells and
rescues them from the effects of cytotoxic compounds
To explore IRF5 function in thyroid cancer cells, we
employed lentiviral vectors to over-express this protein




















































ified cell lines were transduced with either EV or IRF5-GFP and
yroid cancer cells described in A were plated in the absence of drugs
96 hours (black columns) and analyzed for their proliferation. Dashed
after plating and arbitrarily set at 100%. C. The same thyroid cancer
culate their doubling time using the doubling time online calculator
ce intervals were obtained using t-tests determined with the Prism
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with SpeI-NotI adapters in the pLEX-MCS backbone
(Open Biosystems, OHS4735). Transient transfection
into TLA-HEK293 produced recombinant lentiviruses
used to transduce thyroid cancer cells according to the
Open Biosystems TLP4617 protocol. After 72 hours of
puromycin selection (2.5 μg/mL), we performed an anti-
IRF5 immunoblot to confirm transgene expression
(Figure 3A) and 5× 103 resistant cells were placed in
96-well plates to perform ATP-Lite assays according to
the manufacturer’s instructions (PerkinElmer). We found
that IRF5 over-expression conferred a proliferative advan-
tage to three of four thyroid cell lines (SW1736, WRO,
and C643) suggesting a role for IRF5 in promoting thyroid
cancer growth (Figure 3B). These results were further con-
firmed by a significant increase in the proliferation rate of
SW1736 and C643 in doubling time experiments with a
modest effect on WRO cells (Figure 3C).
We also wanted to assess if IRF5 protected neoplastic
thyroid cells from the cytotoxic effects of two DNA-
damaging compounds: doxorubicin (DOXO) and cis-
diamminedichloroplatinum (CDDP). 5 × 103 cell lines
over-expressing IRF5 variant 3 were implanted in 96-well
plates and left untreated or exposed to 2 μM DOXO or
5 μg/mL CDDP. After DOXO or CDDP treatment, ATP-























































































Figure 4 IRF5 protects thyroid cancer cells from the effects of DNA-d
repeated comparing cell growth before and after exposure to 2 μM Doxor
from Sigma). Columns represent average± standard deviation of three inde
calculated as described in the previous figure (*p< 0.05, **p< 0.01, *** p<8305 C, and C643 transduced with IRF5 as compared to
the EV control. IRF5 did not affect WRO cell responsive-
ness to either DOXO or CDDP (Figure 4A, B).
IRF5 increases both clonogenic ability and B-raf
expression in thyroid cancer cells
To establish the tumor-promoting effect of endogenous
IRF5 on thyroid cancer cells, we silenced its expression
using the doxycicline inducible pTRIPZ vector (shRNA
anti-IRF5, gene ID NM_001098627, Open Biosystems). A
non-silencing shRNA (Cat. No. RHS4743) was employed as
a control. Infected thyroid cancer cells were treated with
doxycicline (1 μg/mL) for 72 hours, lysed and blotted for
IRF5 to confirm reduced expression of the transcription
factor. Clonogenic assays were then performed as described
above with doxycicline added every 24 hours to maintain
IRF5 silencing. Reduced IRF5 expression decreased thyroid
cancer colony formation implying that, in thyroid cancer
cells, IRF5 facilitates single cell growth (Figure 5A).
To confirm the increased clonogenic ability of cells
over-expressing IRF5, we compared clones infected with
either pLEX-IRF5-GFP or pLEX-p53-GFP (inserted in
the unique XhoI site of pLEX-MCS). 1 × 103 SW1736,
WRO, C643 and 2 × 103 8305C were plated in a 100 mm
dish and fresh medium was replaced every 72 hours for



























































































amaging agents. A. The experiment described in Figure 3 was
ubicin (DOXO) or 5 μg/mL cis-diamminedichloroplatinum (CDDP) (both







































































































































































































Figure 5 (See legend on next page.)
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Figure 5 IRF5 over-expression increases the foci-forming capacities of thyroid cancer cells. A. Thyroid cells were infected with a
doxycycline (Sigma) (Doxy)-inducible vector encoding either non-silencing or anti-IRF5 shRNA. Three days after doxycycline induction, lysates
were blotted with an anti-IRF5 antibody to confirm reduction of IRF5 expression (left panels). After 1–2 weeks, infected cells were stained for their
foci-forming ability (middle panels). Columns shown in the right panels represent average foci number in each plate ± standard deviation from
three separate experiments (right panels). p-values were determined as reported in Figure 3. B. Thyroid cancer cells transduced with the specified
constructs were analyzed by immunoblot for the expression of IRF5-GFP or p53-GFP (left panels). After 1–2 weeks cells were stained for their
foci-forming ability (middle panels). Graphs depicted in the right panels represent average foci number in each plate ± standard deviation from
three separate experiments. C. The same cells indicated in B, were analyzed for B-Raf (UPSTATE) expression by immunoblot.
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expression induced a significant increase in the total num-
ber of foci generated by three of four cell lines, suggesting
that this protein improves the colony-forming ability of in-
dividual thyroid cancer cells. As expected, p53 drastically
reduced colony formation compared to the EV control
(Figure 5B).
To investigate the molecular mechanism underlying the
unexpected effects of IRF5, we evaluated B-Raf expression,
as this protein is mutated in 30-40% of thyroid carcinomas
[20]. Interestingly, ectopic IRF5 induced endogenous B-Raf
levels in all thyroid cancer cells (Figure 5C).
Discussion
In this study, we report - for the first time - that IRF5 is
expressed in different thyroid carcinoma histotypes and
in multiple thyroid cancer cell lines but is not detectable
in normal human thyrocytes (Figure 1A). In primary
normal and tumor thyroid cancer cells IFNα does not
modulate IRF5 levels (Figure 1B) while in immortalized
cell lines, IRF5 seems oddly responsive to IFNα, since
exposure to this cytokine reduces IRF5 in two thyroid
cancer cells and consistently increases its expression in
one cell line (Figure 1C). We found both endogenous and
ectopic IRF5 in the cytoplasm of thyroid cancer cells and
IFNα was unable to relocate the protein in the nucleus
(Figure 2A, B and Additional file 2). Not surprisingly,
IRF5 did not induce the p21 promoter (Figure 2C, D) [17].
On the contrary, IRF5 stimulated thyroid cancer prolifera-
tion (Figure 3B, C), protected malignant thyroid cells
from the cytotoxic effects of different antiblastic com-
pounds (Figure 4), and significantly increased their colony-
forming ability (Figure 5B). Indeed, silencing of endogenous
IRF5 by lentiviral shRNA reduces the clonogenic potential
of most thyroid cancer cells (Figure 5A). The induction of
B-Raf expression detected in thyroid cells transduced with
IRF5 could partially explain its tumor-promoting effects
(Figure 5C).
These findings pose the pivotal question of what role
is fulfilled by IRF5 in thyroid cancer. The initial observa-
tion that the IRF5 protein is not expressed in normal
thyrocytes but is detected in neoplastic thyroid cells is
somewhat surprising as IRF5 has been usually associatedwith tumor-suppressor rather than tumor-promoting ac-
tivities [8,21,22]. Our finding that thyroid cancer cells
localize IRF5 to the cell cytoplasm implies that the pro-
tein is transcriptionally inactive. Indeed, IRF5 fails to in-
duce a previously characterized target such as p21 and
does not arrest cell-cycle progression. On the contrary,
IRF5 lentiviral over-expression significantly increases the
proliferation rate of malignant thyroid cells. Taken to-
gether these findings suggest two alternative scenarios: a)
IRF5 might be inactivated due to point mutations or
increased tyrosine phosphorylation as previously reported
[22]; b) IRF5 might be either inducing the expression of
tumor-promoting genes or inhibiting the promoters for
tumor-suppressors. Our supplemental data seem to exclude
the first scenario as direct sequencing of IRF5 revealed no
point mutations and we failed to observe any variations in
IRF5 tyrosine phosphorylation levels (Additional file 3).
The second hypothesis seems much more likely as sug-
gested by: i) our findings showing increased B-Raf expres-
sion in thyroid cancer cells lentivirally transduced with
IRF5; ii) the protective effect of IRF5 on thyroid cells
exposed to different cytotoxic drugs; iii) the reduced col-
ony-forming potential of malignant thyrocytes displaying
reduced IRF5 levels.
In summary, the present study indicates that IRF5
favors the thyroid tumoral phenotype. However, the
exact mechanisms underscoring this unexpected bio-
logical function remain partially unresolved.Additional files
Additional file 1: IRF5 shows cytoplasmic localization in thyroid
cancer cells after IFNa treatment. The specified cell lines were treated
with 1000 U/mL IFNa for 24 hours. Cells were then labeled for IRF5 using
the indicated secondary antibody. Hoechst and phalloidin were
employed to stain nuclear and cytoplasmic compartments.
Additional file 2: IRF5 v3 shows cytoplasmic localization in thyroid
cancer cells. The specified cell lines were lentivirally infected with
IRF5-GFP v3 and the proteins intracellular localization was analyzed by
immunofluorescence.
Additional file 3: IRF5 tyrosine phosphorylation is not modulated
by DNA-damaging agents in thyroid cancer cells. Whole lysates of
the specified cell lines treated with 2 μM Doxorubicin (DOXO) or 5 μg/
mL cisdiamminedichloroplatinum (CDDP) for the indicated times were
subjected to an anti-phosphotyrosine (pY) immunoprecipitaion and
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loading control.
Abbreviations
IRF5: Interferon Regulatory Factor-5; IFNα: Interferon-alpha; GFP: Green
Fluorescence Protein; Luc: Luciferase; EV: Empty Vector; MCS: Multiple
Cloning Site; DOXO: Doxorubicine; CDDP: Cis-diamminedichloroplatinum;
shRNA: Short-Hairpin RNA; Doxy: Doxycicline.
Competing interests
The authors declare that they have no competing interests.
Acknowledgements
This work was supported by the Italian Association for Cancer Research
(AIRC).
Author details
Department of Clinical and Molecular Bio-Medicine, University of Catania,
Via Androne, 83-95124 Catania, ITALY.
Authors’ contributions
MM, MF, AF and AA carried out the research. FF participated in coordination
and data analysis. LM and PV designed the study and drafted the
manuscript. All authors read and approved the final manuscript.
Received: 12 September 2011 Accepted: 16 April 2012
Published: 16 April 2012
References
1. Battistini A: Interferon regulatory factors in hematopoietic cell
differentiation and immune regulation. J Interferon Cytokine Res 2009,
29:765–780.
2. Takaoka A, Tamura T, Taniguchi T: Interferon regulatory factor family of
transcription factors and regulation of oncogenesis. Cancer Sci 2008,
99:467–478.
3. Barnes B, Lubyova B, Pitha PM: On the role of IRF in host defense.
J Interferon Cytokine Res 2002, 22:59–71.
4. Manzella L, Conte E, Cocchiaro G, Guarniera E, Sciacca B, Bonaiuto C, Stagno
F, Messina A: Role of interferon regulatory factor 1 in monocyte/
macrophage differentiation. Eur J Immunol 1999, 29:3009–3016.
5. Manzella L, Gualdi R, Perrotti D, Nicolaides NC, Girlando G, Giuffrida MA,
Messina A, Calabretta B: The interferon regulatory factors 1 and 2 bind to
a segment of the human c-myb first intron: possible role in the
regulation of c-myb expression. Exp Cell Res 2000, 256:248–256.
6. Yanai H, Chen HM, Inuzuka T, Kondo S, Mak TW, Takaoka A, Honda K,
Taniguchi T: Role of IFN regulatory factor 5 transcription factor in
antiviral immunity and tumor suppression. Proc Natl Acad Sci U S A 2007,
104:3402–3407.
7. Tamura T, Yanai H, Savitsky D, Taniguchi T: The IRF family transcription
factors in immunity and oncogenesis. Annu Rev Immunol 2008, 26:
535–584.
8. Hu G, Barnes BJ: IRF-5 is a mediator of the death receptor-induced
apoptotic signaling pathway. J Biol Chem 2009, 284:2767–2777.
9. Barnes BJ, Moore PA, Pitha PM: Virus-specific activation of a novel
interferon regulatory factor, IRF-5, results in the induction of distinct
interferon alpha genes. J Biol Chem 2001, 276:23382–23390.
10. Mori T, Anazawa Y, Iiizumi M, Fukuda S, Nakamura Y, Arakawa H:
Identification of the interferon regulatory factor 5 gene (IRF-5) as a
direct target for p53. Oncogene 2002, 21:2914–2918.
11. Barnes BJ, Field AE, Pitha-Rowe PM: Virus-induced heterodimer formation
between IRF-5 and IRF-7 modulates assembly of the IFNA
enhanceosome in vivo and transcriptional activity of IFNA genes.
J Biol Chem 2003, 278:16630–16641.
12. Barnes BJ, Richards J, Mancl M, Hanash S, Beretta L, Pitha PM: Global and
distinct targets of IRF-5 and IRF-7 during innate response to viral
infection. J Biol Chem 2004, 279:45194–45207.
13. Fagin JA: Minireview: branded from the start-distinct oncogenic initiating
events may determine tumor fate in the thyroid. Mol Endocrinol 2002,
16:903–911.14. Fagin JA: Perspective: lessons learned from molecular genetic studies of
thyroid cancer-insights into pathogenesis and tumor-specific therapeutic
targets. Endocrinology 2002, 143:2025–2028.
15. Giuffrida D, Gharib H: Anaplastic thyroid carcinoma: current diagnosis and
treatment. Ann Oncol 2000, 11:1083–1089.
16. Tirro E, Consoli ML, Massimino M, Manzella L, Frasca F, Sciacca L, Vicari L,
Stassi G, Messina L, Messina A, Vigneri P: Altered expression of c-IAP1,
survivin, and Smac contributes to chemotherapy resistance in thyroid
cancer cells. Cancer Res 2006, 66:4263–4272.
17. Barnes BJ, Kellum MJ, Pinder KE, Frisancho JA, Pitha PM: Interferon
regulatory factor 5, a novel mediator of cell cycle arrest and cell death.
Cancer Res 2003, 63:6424–6431.
18. Lin R, Yang L, Arguello M, Penafuerte C, Hiscott J: A CRM1-dependent
nuclear export pathway is involved in the regulation of IRF-5 subcellular
localization. J Biol Chem 2005, 280:3088–3095.
19. Barnes BJ, Kellum MJ, Field AE, Pitha PM: Multiple regulatory domains of
IRF-5 control activation, cellular localization, and induction of
chemokines that mediate recruitment of T lymphocytes. Mol Cell Biol
2002, 22:5721–5740.
20. Salvatore G, De Falco V, Salerno P, Nappi TC, Pepe S, Troncone G,
Carlomagno F, Melillo RM, Wilhelm SM, Santoro M: BRAF is a therapeutic
target in aggressive thyroid carcinoma. Clin Cancer Res 2006, 12:
1623–1629.
21. Hu G, Mancl ME, Barnes BJ: Signaling through IFN regulatory factor-5
sensitizes p53-deficient tumors to DNA damage-induced apoptosis and
cell death. Cancer Res 2005, 65:7403–7412.
22. Couzinet A, Tamura K, Chen HM, Nishimura K, Wang Z, Morishita Y, Takeda
K, Yagita H, Yanai H, Taniguchi T, Tamura T: A cell-type-specific
requirement for IFN regulatory factor 5 (IRF5) in Fas-induced apoptosis.
Proc Natl Acad Sci U S A 2008, 105:2556–2561.
doi:10.1186/1476-4598-11-21
Cite this article as: Massimino et al.: IRF5 promotes the proliferation of
human thyroid cancer cells. Molecular Cancer 2012 11:21.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
